2021
DOI: 10.1016/j.xinn.2021.100116
|View full text |Cite
|
Sign up to set email alerts
|

Genomic variation, origin tracing, and vaccine development of SARS-CoV-2: A systematic review

Abstract: COVID-19 has spread globally to over 200 countries with more than 40 million confirmed cases and one million deaths as of November 1, 2020. The SARS-CoV-2 virus, leading to COVID-19, shows extremely high rates of infectivity and replication, and can result in pneumonia, acute respiratory distress, or even mortality. SARS-CoV-2 has been found to be continue rapidly evolving, with several genomic variants emerging in different regions throughout the world. In addition, despite intensive study of the spike protei… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
5

Citation Types

0
42
0
1

Year Published

2021
2021
2022
2022

Publication Types

Select...
7
2
1

Relationship

1
9

Authors

Journals

citations
Cited by 46 publications
(43 citation statements)
references
References 115 publications
0
42
0
1
Order By: Relevance
“…Despite intensive research within the last year, only few treatments for COVID-19 are currently available (Kim et al 2020 ; Kluge et al 2021 ; WHO Solidarity Trial Consortium 2021 ), and to date, no effective measures are known to improve conditions of long COVID or neuroCOVID (Llach and Vieta 2021 ). This scarcity of options for the management of COVID-19 and the emergence of ‘immune escape’ against established vaccines plus ‘breakthrough infections’ (Birhane et al 2021 ; Edara et al 2021 ; Garcia-Beltran et al 2021 ; Li et al 2021 ; Plante et al 2021 ; Prevost and Finzi 2021 ; Thorne et al 2021 ; Wall et al 2021 ; Zhou et al 2021 ), reducing the hope of a speedy termination of the pandemic, call for new strategies to treat COVID-19. Based on the known neuroprotective and anti-inflammatory features of EPO, and its proven efficacy and excellent tolerability in different neuropsychiatric conditions (Ehrenreich et al 2020 ; Miskowiak et al 2021 ; Sargin et al 2010 ; Sirén et al 2009 ), we proposed the use of recombinant human (rh) EPO for the treatment of severely affected COVID-19 patients.…”
Section: Introductionmentioning
confidence: 99%
“…Despite intensive research within the last year, only few treatments for COVID-19 are currently available (Kim et al 2020 ; Kluge et al 2021 ; WHO Solidarity Trial Consortium 2021 ), and to date, no effective measures are known to improve conditions of long COVID or neuroCOVID (Llach and Vieta 2021 ). This scarcity of options for the management of COVID-19 and the emergence of ‘immune escape’ against established vaccines plus ‘breakthrough infections’ (Birhane et al 2021 ; Edara et al 2021 ; Garcia-Beltran et al 2021 ; Li et al 2021 ; Plante et al 2021 ; Prevost and Finzi 2021 ; Thorne et al 2021 ; Wall et al 2021 ; Zhou et al 2021 ), reducing the hope of a speedy termination of the pandemic, call for new strategies to treat COVID-19. Based on the known neuroprotective and anti-inflammatory features of EPO, and its proven efficacy and excellent tolerability in different neuropsychiatric conditions (Ehrenreich et al 2020 ; Miskowiak et al 2021 ; Sargin et al 2010 ; Sirén et al 2009 ), we proposed the use of recombinant human (rh) EPO for the treatment of severely affected COVID-19 patients.…”
Section: Introductionmentioning
confidence: 99%
“…Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has been identified among patients in China since December 2019. The infection has rapidly spread worldwide ( 1 ). As a newly emerging infectious disease, details regarding COVID-19 are not yet fully elucidated.…”
Section: Introductionmentioning
confidence: 99%
“…Распространившись по всему миру, с декабря 2019 года этиологический агент COVID-19 в ходе своей эволюции, претерпел различные изменения в геноме, сформировав множество штаммов -геновариантов [2,3,4]. Считается, что эпидемическую значимость представляют штаммы имеющие изменения в гене шипового гликопротеина («S gene» от англ.…”
Section: Introductionunclassified